Search Results - "Rudick, Richard A."

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis by Strober, Lauren, DeLuca, John, Benedict, Ralph HB, Jacobs, Adam, Cohen, Jeffrey A, Chiaravalloti, Nancy, Hudson, Lynn D, Rudick, Richard A, LaRocca, Nicholas G

“…Background: The need for more robust outcomes in multiple sclerosis (MS) clinical trials has been a main priority of the field for decades. Dissatisfaction…”
Get full text

Gray matter atrophy in multiple sclerosis: A longitudinal study by Fisher, Elizabeth, Lee, Jar-Chi, Nakamura, Kunio, Rudick, Richard A.

“…Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at all stages of disease, and to identify predictors and clinical…”
Get full text

Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study by Trapp, Bruce D, Vignos, Megan, Dudman, Jessica, Chang, Ansi, Fisher, Elizabeth, Staugaitis, Susan M, Battapady, Harsha, Mork, Sverre, Ontaneda, Daniel, Jones, Stephen E, Fox, Robert J, Chen, Jacqueline, Nakamura, Kunio, Rudick, Richard A

“…Demyelination of cerebral white matter is thought to drive neuronal degeneration and permanent neurological disability in individuals with multiple sclerosis…”
Get full text

Measurement and clinical effect of grey matter pathology in multiple sclerosis by Geurts, Jeroen JG, Prof, Calabrese, Massimiliano, MD, Fisher, Elizabeth, PhD, Rudick, Richard A, Prof

“…Summary During the past 10 years, the intense involvement of the grey matter of the CNS in the pathology of multiple sclerosis has become evident. On gross…”
Get full text

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study by OʼConnor, Paul, Goodman, Andrew, Kappos, Ludwig, Lublin, Fred, Polman, Chris, Rudick, Richard A, Hauswirth, Kathy, Cristiano, Lynda M, Forrestal, Fiona, Duda, Petra

“…OBJECTIVES:Report long-term safety and effectiveness of natalizumab over 240 weeks in the prospective, observational, open-label Safety of TYSABRI Re-dosing…”
Get full text

Oral treatment for multiple sclerosis by Killestein, Joep, Dr, Rudick, Richard A, Prof, Polman, Chris H, Prof

“…Summary Background The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have…”
Get full text

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis by Rudick, Richard A, MD, Polman, Chris H, MD

“…Summary Disease-modifying drugs (DMDs) for relapsing-remitting multiple sclerosis (RRMS) are only partly effective—breakthrough disease commonly occurs despite…”
Get full text

Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic by Erbayat Altay, Edru, Fisher, Elizabeth, Jones, Stephen E, Hara-Cleaver, Claire, Lee, Jar-Chi, Rudick, Richard A

“…To assess the reliability of new magnetic resonance imaging (MRI) lesion counts by clinicians in a multiple sclerosis specialty clinic. An observational study…”
Get more information

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) by Mowry, Ellen M, Bermel, Robert A, Williams, James R, Benzinger, Tammie L S, de Moor, Carl, Fisher, Elizabeth, Hersh, Carrie M, Hyland, Megan H, Izbudak, Izlem, Jones, Stephen E, Kieseier, Bernd C, Kitzler, Hagen H, Krupp, Lauren, Lui, Yvonne W, Montalban, Xavier, Naismith, Robert T, Nicholas, Jacqueline A, Pellegrini, Fabio, Rovira, Alex, Schulze, Maximilian, Tackenberg, Björn, Tintore, Mar, Tivarus, Madalina E, Ziemssen, Tjalf, Rudick, Richard A

“…Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS)…”
Get full text

Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform by Lee, Stephen, Plavina, Tatiana, Singh, Carol M., Xiong, Kuangnan, Qiu, Xiaolei, Rudick, Richard A., Calabresi, Peter A., Stevenson, Lauren, Graham, Danielle, Raitcheva, Denitza, Green, Christopher, Matias, Madeleine, Uzgiris, Arejas J.

“…Background Neurofilament light chain (NfL) is an axonal cytoskeletal protein that is released into the extracellular space following neuronal or axonal injury…”
Get full text

Possible clinical outcome measures for clinical trials in patients with multiple sclerosis by Goldman, Myla D., Motl, Robert W., Rudick, Richard A.

“…Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease with both clinical and pathological heterogeneity. The complexity of the MS…”
Get full text

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring by Kappos, Ludwig, Prof, Bates, David, MD, Hartung, Hans-Peter, MD, Havrdova, Eva, MD, Miller, David, MD, Polman, Chris H, MD, Ravnborg, Mads, MD, Hauser, Stephen L, MD, Rudick, Richard A, MD, Weiner, Howard L, MD, O'Connor, Paul W, MD, King, John, MD, Radue, Ernst Wilhelm, MD, Yousry, Tarek, MD, Major, Eugene O, PhD, Clifford, David B, MD

“…Summary Natalizumab is a new treatment option for patients with active relapsing-remitting multiple sclerosis. In phase III studies, natalizumab was highly…”
Get full text

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients by Rudick, Richard A., O'Connor, Paul W., Polman, Chris H., Goodman, Andrew D., Ray, Soma S., Griffith, Nancy M., Jurgensen, Stephanie A., Gorelik, Leonid, Forrestal, Fiona, Sandrock, Alfred W., E. Goelz, Susan

“…Objective Analyses were conducted to determine the clinical utility of measuring JC virus (JCV) DNA in blood or urine of natalizumab‐treated multiple sclerosis…”
Get full text

Imaging correlates of axonal swelling in chronic multiple sclerosis brains by Fisher, Elizabeth, Chang, Ansi, Fox, Robert J., Tkach, Jean A., Svarovsky, Therese, Nakamura, Kunio, Rudick, Richard A., Trapp, Bruce D.

“…Objective T2‐weighted magnetic resonance imaging is a sensitive tool for monitoring progression of multiple sclerosis, but it does not provide information on…”
Get full text

Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study by Rudick, Richard A., Lee, Jar-Chi, Simon, Jack, Fisher, Elizabeth

“…Objective To evaluate the relation between T2 lesions and disease severity in relapsing‐remitting multiple sclerosis (MS). Methods This article describes a…”
Get full text

Measuring treatment response to advance precision medicine for multiple sclerosis by Calabresi, Peter A., Kappos, Ludwig, Giovannoni, Gavin, Plavina, Tatiana, Koulinska, Irene, Edwards, Michael R., Kieseier, Bernd, Moor, Carl, Sotirchos, Elias S., Fisher, Elizabeth, Rudick, Richard A., Sandrock, Alfred

“…Objective To assess the independent contributions of clinical measures (relapses, Expanded Disability Status Scale [EDSS] scores, and neuroperformance…”
Get full text

Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability by Brier, Matthew R., Snyder, Abraham Z., Tanenbaum, Aaron, Rudick, Richard A., Fisher, Elizabeth, Jones, Stephen, Shimony, Joshua S., Cross, Anne H., Benzinger, Tammie L. S., Naismith, Robert T.

“…Objective To enable use of clinical magnetic resonance images (MRIs) to quantify abnormalities in normal appearing (NA) white matter (WM) and gray matter (GM)…”
Get full text

role of cell type-specific responses in IFN-β therapy of multiple sclerosis by Zula, Joana A, Green, Holly C, Ransohoff, Richard M, Rudick, Richard A, Stark, George R, van Boxel-Dezaire, Anette H. H

“…The mechanism of IFN-β therapy in relapsing-remitting multiple sclerosis (RRMS) is not well understood, but induction of apoptosis in specific leukocyte…”
Get full text

Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis by Rudick, Richard A, Rani, M R Sandhya, Xu, Yaomin, Lee, Jar-Chi, Na, Jie, Shrock, Jennifer, Josyula, Anupama, Fisher, Elizabeth, Ransohoff, Richard M

“…Interferon-beta (IFNβ) is used to inhibit disease activity in multiple sclerosis (MS), but its mechanisms of action are incompletely understood, individual…”
Get full text

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta by Bermel, Robert A., You, Xiaojun, Foulds, Pamela, Hyde, Robert, Simon, Jack H., Fisher, Elizabeth, Rudick, Richard A.

“…Objective: To identify early predictors of long‐term outcomes in patients with relapsing–remitting multiple sclerosis (RRMS) treated with intramuscular (IM)…”
Get full text